نتایج جستجو برای: daclizumab

تعداد نتایج: 624  

Journal: :Haematologica 2007
Milena Elimelakh Vanessa Dayton Katharine S Park Angelika C Gruessner David Sutherland Robert B Howe Mark T Reding Ted Eastlund Jo-Anne van Burik Timothy P Singleton Rainer W Gruessner Nigel S Key

BACKGROUND AND OBJECTIVES Acquired red cell aplasia (RCA) is a rare disorder and can be either idiopathic or associated with certain diseases, pregnancy, or drugs. In exceptionally rare cases, it has been reported to co-exist with other autoimmune cytopenias. We report a high incidence of RCA and autoimmune hemolytic anemia (AIHA) in pancreas transplant recipients on alemtuzumab-based maintenan...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013
Deepali Kumar Atul Humar

In the past decade, there has been major progress in the development of novel immunosuppressive therapies. In addition, there have been advances in the clinical applications of these therapies to suppress both alloimmunity and autoimmunity. In some situations, however, the toxicity of the therapies, including infections, can limit their use. In this issue of Clinical Infectious Diseases, Loeche...

Journal: :Haematologica 2008
Herwig Lackner Christian Urban Petra Sovinz Martin Benesch Andrea Moser Wolfgang Schwinger

Hemophagocytic lymphohistiocytosis (HLH) during childhood cancer treatment is a rare adverse event posing major diagnostic and therapeutic challenges. Between 1995 and 2006, 6 children developed HLH while on conventional chemotherapy (n=4) or after allogeneic stem cell transplantation (n=2). Treatment of HLH included dexamethasone and etoposide, 2 children additionally received infliximab or da...

Journal: :American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009
H Ekberg C Bernasconi H Tedesco-Silva S Vítko C Hugo A Demirbas R Reyes Acevedo J Grinyó U Frei Y Vanrenterghem P Daloze P Halloran

The Symphony study showed that at 1 year posttransplant, a regimen based on daclizumab induction, 2 g mycophenolate mofetil (MMF), low-dose tacrolimus and steroids resulted in better renal function and lower acute rejection and graft loss rates compared with three other regimens: two with low-doses of cyclosporine or sirolimus instead of tacrolimus and one with no induction and standard cyclosp...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید